

REMARKS

Claims 24-30 and 38-59 are pending. Claims 25-30 and 56 and portions of the specification have been amended to correct typographical errors and to insert the SEQ ID NO identifiers associated with the sequences listed in the accompanying Sequence Listing. Claim 56 was also amended to include an option at position Z which had been inadvertently left out.

Support for the inclusion of SEQ ID NO identifiers and amendment to claim 56 can be found, for example, at pages 16-17, and pages 43-45, 48 and 49 of the substitute specification filed May 10, 2005. Accordingly, no new matter is added by these amendments.


Applicants respectfully request entry of the substitute sequence listing submitted herewith. Applicants respectfully request entry of this amendment and believe that the present application is now in condition for allowance. The Examiner is encouraged to call the undersigned to discuss any issues related to the prosecution of the instant application.

No fees are believed due for this submission. However, if a fee is due, the Commissioner is hereby authorized to charge payment of any fees associated with this communication, to Applicant's Deposit Account No. 010535. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.

Date: April 5, 2006



Karen R. Zachow, Ph.D.
Registration No. 46,332

AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Telephone: (858) 552-2200
Facsimile: (858) 552-1936